Jane Street Group LLC Has $2.32 Million Stock Holdings in Personalis, Inc. (NASDAQ:PSNL)

Jane Street Group LLC lifted its position in shares of Personalis, Inc. (NASDAQ:PSNL) by 144.3% during the 4th quarter, Holdings Channel reports. The firm owned 401,314 shares of the company’s stock after purchasing an additional 237,033 shares during the quarter. Jane Street Group LLC’s holdings in Personalis were worth $2,320,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the company. abrdn plc bought a new stake in shares of Personalis during the 4th quarter worth about $1,722,000. Dimensional Fund Advisors LP boosted its holdings in shares of Personalis by 144.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company’s stock worth $2,372,000 after buying an additional 242,141 shares during the period. Blue Water Life Science Advisors LP boosted its holdings in shares of Personalis by 13.3% during the 4th quarter. Blue Water Life Science Advisors LP now owns 1,132,900 shares of the company’s stock worth $6,548,000 after buying an additional 132,900 shares during the period. Jump Financial LLC bought a new stake in shares of Personalis during the 4th quarter worth about $588,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Personalis during the 4th quarter worth about $275,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on PSNL shares. Guggenheim started coverage on shares of Personalis in a report on Thursday. They issued a “buy” rating and a $6.00 price objective for the company. HC Wainwright upped their price target on shares of Personalis from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, May 7th. Craig Hallum initiated coverage on shares of Personalis in a report on Monday, March 17th. They set a “buy” rating and a $8.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 price target on shares of Personalis in a report on Thursday, April 10th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Personalis presently has an average rating of “Buy” and an average price target of $7.67.

Personalis Trading Up 1.5%

Shares of Personalis stock opened at $4.89 on Friday. The company has a 50 day moving average of $3.74 and a 200-day moving average of $4.47. The company has a market cap of $431.91 million, a PE ratio of -2.91 and a beta of 1.83. Personalis, Inc. has a 1-year low of $1.14 and a 1-year high of $7.20.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. The business had revenue of $20.61 million during the quarter, compared to the consensus estimate of $17.41 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. Research analysts forecast that Personalis, Inc. will post -1.4 earnings per share for the current year.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.